Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
2. Introduction
●Defined as a serum [Na] below 135 mmol/L.
●Most common disorder of electrolytes encountered in
clinical practice, occurring in 22% of hospitalized
patients.
3. Important clinically because:
1)acute severe hyponatremia can cause substantial
morbidity and mortality;
2)adverse outcomes are higher in hyponatremic
patients with a wide range of underlying diseases;
3)overly rapid correction of chronic hyponatremia can
cause severe neurological deficits and death.
6. Vomiting or
Diarrhoea
Burns
Peritonitis
Bowel lumen ileus
Loss water &
Na+, Cl --
free water or hypotonic
fluid intake
Gastrointestinal and Third-Space
Sequestered Losses
Hypovolemic
hyponatremia
Vasopressin
due to volume
contraction
7. Loop diuretics
In TALH
Blocks sodium
reabsorption
interferes with the
generation of a hypertonic
medullary interstitium
Thiazide
diuretics
DCT
interfering with urinary
dilution rather than with
urinary concentration
More free water excretion,
inspite of vasopressin
Limits free water
excretion
Diuretic therapy
8. Is a syndrome described following SAH, head injury, or
neurosurgical procedures, as well in other settings.
Primary defect is salt wasting from the kidneys(?role of
BNP) with subsequent volume contraction, which
stimulates vasopressin release.
Uncommon.
Cerebral Salt Wasting
syndrome
9. Characterized by hyponatremia with ECF volume
contraction (provides the nonosmotic stimulus for
vasopressin release).
Urine [Na+
] above 20 mmol/l, and high serum K+
.
Mineralocorticoid (Aldosterone) Deficiency
11. A defect in osmoregulation causes vasopressin to be
inappropriately stimulated, leading to urinary concentration.
MCC of euvolumic hyponatremia
Excess vasopressin: CNS disturbances such as hemorrhage,
tumors, infections, and trauma.
Ectopic vasopressin: Small cell lung cancers, cancer of the
duodenum and pancreas, and olfactory neuroblastoma.
Idiopathic: seen in elderly(10%).
SIADH (Syndrome of Inappropriate ADH Secretion)
12. Criteria for Diagnosing SIADH
➢Decreased effective osmolality of the extracellular fluid.
➢Inappropriate urinary concentration (Uosm >100 mOsmol/kg
H2O) with normal renal function) at some level of plasma hypo-
osmolality.
➢Clinical euvolemia.
➢Elevated urinary sodium excretion (>20 mmol/L) while
on normal salt and water intake.
➢Absence of other potential causes of euvolemic hypo-osmolality
➢Normal renal function and absence of diuretic use, particularly
thiazide diuretics.
13. Supporting diagnostic criteria for SIADH
➢ Serum uric acid <4 mg/dL
➢ Blood urea nitrogen <10 mg/dL
➢Fractional sodium excretion >1%; fractional urea
excretion >55%
➢Failure to improve or worsening of hyponatremia after
0.9% saline infusion
➢ Improvement of hyponatremia with fluid restriction
19. ↑plasma renin,
↑ norepinephrine,
↑ vasopressin
↓GFR, ↑free water retention
Dilutional hyponatremia
Cirrhosis
In pts of advanced cirrhosis
↑extracellular volume (ascites, edema).
↑ plasma volume (splanchnic venous dilation)
20. Advanced Chronic kidney disease
•Urine output is relatively fixed and water intake in
excess of urine output and insensible losses will cause
hyponatremia.
•Edema usually develops when the Na+ ingested exceeds
the kidneys capacity to excrete.
23. STEP 1 – Serum Osmolality
●Serum Osmolality:lab value or calculation – in
mosm/kg
●=(2 x Na+) + (glucose/18) + (BUN/2.8)
●Hypertonic - >295
●hyperglycemia, mannitol, glycerol
●Isotonic - 280-295
●pseudo-hyponatremiafrom elevated lipids or protein
●Hypotonic - <280
●excess fluid intake,low solute intake,renal disease,SIADH,
hypothyroidism,adrenal insufficiency,CHF,cirrhosis,etc.
24. STEP 2 –Volume Status
●2ndassessvolume status (extracellular fluid volume)
●Hypotonic hyponatremia has3 main etiologies:
●Hypovolemic– both water and Na decreased (H20 < Na)
●Consider obvious lossesfrom diarrhea, vomiting,
dehydration, malnutrition, etc
●Euvolemic – water increased and Na stable
●Consider SIADH,thyroid disease,primary polydipsia
●Hypervolemic – water increased and Na increased (H2O > Na)
●Consider obvious CHF
, cirrhosis, renal failure
25. STEP 3 – Urine Studies
●For euvolemic hyponatremia, check urine osmolality
●Urine osmolality <100 - excess water intake
●Primarypolydipsia, tap water enemas, post-TURP
●Urine osmolality >100 - impaired renal concentration
●SIADH, hypothyroidism, cortisol deficiency
●Checkurine sodium &calculate FeNa%
●Low urine sodium (<20) and low FeNa(<1%) implies the
kidneysare appropriatelyreabsorbing sodium
●High urine sodium (>20) and high FeNa(>1%) implies the
kidneys are not functioning properly
26.
27. Treatment
●When considering the treatment of patients with
hyponatremia, five issues must be addressed:
• Risk of osmotic demyelination
Appropriate rate of correction to minimize this risk
•
•
•
•
•
Optimal method of raising the plasma sodium
concentration
Estimation of the sodium deficit if sodium is to be
given
Management of the patient in whom overly rapid
correction has occurred
28. General principles of treatment
●.Primarily determined by the severity of symptoms and
the cause of the hyponatremia
• Symptomatic hyponatremia (seizures, or coma)
o likely to occur with an acute case and marked
reduction in the plasma sodium concentration
o Aggressive therapy is required.
o Chronic but significant hyponatremia
where less severe neurologic symptoms occur
fatigue, nausea, dizziness, gait disturbances,
confusion, lethargy, and muscle cramps
These symptoms typically do not mandate
aggressive therapy
29. Methods of Sodium Correction
• Water restriction
• primary therapy for hyponatremia in edematous states,
SIADH, primary polydipsia, and advanced renal failure.
• Sodium chloride administration
•
• usually as isotonic saline or increased dietary salt
given to patients with true volume depletion, adrenal
insufficiency, and in some cases of SIADH.
contraindicated in edematous patients (eg, heart
failure, cirrhosis, renal failure) since it will lead to
exacerbation of the edema
•Hypertonic saline is generally recommended only for
patients with symptomatic or severe hyponatremia.
30. • The increase in plasma Na+concentration can be highly
unpredictable during treatment with hypertonic saline due
to rapid changes in the underlying physiology.
• Patient should be monitored carefully for changes in
neurologic and pulmonary status, and serum electrolytes
should be checked frequently, every 2 - 4 hours.
31. Goal:
●Urgent correction by 1-2 mmol/hr upto 4-6 mmol/L, to
prevent brain herniation and neurological damage from
cerebral ischemia.
●Upper limit for correction,10-12 mmol/L in any 24hour
period; 18 mmol/L in any 48-hour period.
Treatment of symptomatic acute hyponatremia
32. how much fluids to give?
➢ Total body water = weight x 0.6 for men / 0.5 for woman
• One liter of NS contains: 154 mmol/L of Na+ Cl−
• One liter of 3% saline contains:513 mmol/L of Na+ Cl−
33. ●Example:An60-kg man is havingseizure .His s.Na is 110
mmol / L.
● Meansofcorrection:
●Given the acuity,the patient should be givenhypertonic saline,
which has 513 mmol ofNaper liter.
● {513 - 110} /{60 x 0.6 +1}= 10 mmol/L
● One liter of thisfluid would increase Naby10 mmol/ L.
Dose of hypertonicsaline at 200 mL/ hr until symptoms
improve. Maximum 1 litre of3% NS should be given in 24
hour.
34. Goal:
●Minimum correction of serum [Na] by 4-8 mmol/L per
day, with a lower goal of 4-6 mmol/L per day if the risk of
ODS is high.
Limits not to exceed:
• 8-10 mmol/L in any 24-hour period.
Treatment of chronic hyponatremia(Avoiding
ODS)
35. Treatment of hypovolemic hyponatremia
➢Diuretic related- Discontinuation of thiazides and
correction of volume deficits.
➢Mineralocorticoid deficiency- Volume repletion with
isotonic saline, Fludrocortisone chronically for
mineralocorticoid replacement.
36. SIADH - For most cases of mild-to moderate SIADH, fluid
restriction represents the cheapest and least toxic therapy. (fluid
restriction 500 mL/d below the 24-hour urine volume.
Failure to water restriction
- Vaptans
- Democlocycline 150- 300 mg PO tid or qid
-Fludrocortisone 0.05-0.2 mg bid
Treatment of euvolemic hyponatremia
37. Glucocorticoid Deficiency-glucocorticoid replacement
at either maintenance or stress doses, depending on
the degree of intercurrent illness.
Severe Hypothyroidism-thyroid hormone replacement at
standard weight-based doses; several days may be needed
to normalize the serum [Na].
38. Heart Failure-for patients with mild to moderate
symptoms, begin with fluid restriction (1 L/d total) and, if
signs of volume overload are present, administer loop
diuretics.
If the serum [Na] does not correct to the desired level, lift the
fluid restriction and start either conivaptan or tolvaptan.
Treatment of hypovolemic hyponatremia
39. ❑
Cirrhosis-Severe daily fluid restriction,
Vaptans an alternative choice if fluid restriction has failed to maintain
a serum [Na] 130 mmol/L; however, tolvaptan use should be
restricted to cases where the potential clinical benefit outweighs the
risk of worsened liver function, such as in patients with end-stage
liver disease and severe hyponatremia who are awaiting imminent
liver transplantation.
40. CKD-Restricting fluid intake.Aquaretics (vaptans)
can be employed{not be expected to cause a
clinically significant aquaresis with severe renal
impairment (ie, serum creatinine >2.5 mg/dL)}.
41. Role of VAPTANS
➢ Vaptans have long been anticipated as a more effective
method to treat hyponatremia by virtue of their unique effect
to selectively increase solute-free water excretion by the
kidneys.
➢ Although not C/I with decreased renal function, these
agents generally will not be effective if S.Cr is >2.5mg%.
42. Conivaptan Tolvaptan Lixivaptan
Receptor V1a/V2 antagonist V2 antagonist V2 antagonist
Route i.v Oral Oral
Urine volume ↑ ↑ ↑
Urine
osmolality
↓ ↓ ↓
Sodium
excretion/d
↔ ↔ ↔ at low dose,
↑at high dose
Status FDA approved FDA & EMA approved Phase 3
completed
Dosage 20mg over 30min f/b cont
inf 20-40mg/d
15mg on D1, then titrate to
30-60mg/d
-
Duration of
treatment
Max 4days (interaction with
CYP3A4)
≤30days(risk of hepatic
injury)
-
Side effects Headache, thirst,
hypokalemia
Drymouth, thirst, dizziness,
hypotension
-
Indications Euvolumic and
hypervolumic hyponatremia
Euvolumic and hypervolumic
hyponatremia
-
44. ➢ODS occurs if chronic hyponatremia is corrected too
rapidly.
Present in a stereotypical biphasic pattern (initially
improve neurologically with correction of hyponatremia,
but then, one to several days later, new, progressive, and
sometimes permanent neurological deficits emerge).
45. • Patients can present para- or quadraparesis, dysphagia,
dysarthria, diplopia, a "locked-in syndrome," and/or loss of
consciousness.
• Most commonly affected area is pons.
• Other regions of the brain affected in ODS: (in order of
frequency) cerebellum, lateral geniculate body, thalamus,
putamen, and cerebral cortex or subcortex.
46. • As these lesions may not appear until 2 weeks after development, a diagnosis
of myelinolysis should not be excluded if the imaging is initially normal.
47. Starting serum [Na] ≥120 mmol/L: Intervention unnecessary.
Starting serum [Na] <120 mmol/L:
▪Withhold the next dose of vaptan if the correction is >8
mmol/L;
▪Consider therapeutic re-lowering of serum [Na] if
correction exceeds therapeutic limits;
▪Consider administration of high-dose glucocorticoids (eg,
dexamethasone, 4 mg every 6 hrs) for 24-48hrs following
the excessive correction.
Managing excessive correction of chronic hyponatremia
48. Re-lowering serum [Na]:
▪Administer desmopressin to prevent further water losses:
2-4 mg every 8 hours parenterally;
▪Replace water orally or as 5% dextrose in water
intravenously: 3 mL/kg/h;
▪Recheck serum [Na] hourly and continue therapy infusion
until serum [Na] is reduced to goal
49. Hypotonic hyponatremia/true
hyponatremia
Pseudohyponatremia/osmotic related
Prim
aryrenal disease
Impaired renal
function
Access
volume
status
Accessrenal
status
Normal
Volumedepletion
Edema–CHF, cirrhosis,nephrotic syndrome
Ur, Na+ <20= diarrhoea,
vomiting, burns, pancreatitis
Ur, Na+ >20= diuretics, salt
losingnephropathy
Norm
al volume
Adrenal &thyroid
function
Adrenal &thyroidinsufficiency
Normal
AccessUrine
osmolality(Ableto
diluteurine)
>100 mOsmol/kg H2O
Diluteurine Psychogenicpolydipsia
NO
YES
Accessserumosmolality
low
Normal/high
SIADH
Approach to a case of hyponatremia